Advertisement

Search Results

Advertisement



Your search for Susan London matches 119 pages

Showing 1 - 50


ASCO, Conquer Cancer Congratulate 2019 Grant and Award Recipients

Conquer Cancer®, the ASCO Foundation, presented more than $7 million in grants and awards to exceptional oncology researchers at the 2019 ASCO Annual Meeting. ASCO and Conquer Cancer congratulate the recipients and offer their profound thanks to those who generously supported these awards. Visit...

Growing Up in a Medical Family Planted the Seed for a Career in Oncology for Karen Gelmon, MD

Karen Gelmon, MD, was born and reared in Saskatoon, the largest city in the Canadian province of Saskatchewan. It is surrounded by vast prairie and situated along the Trans-Canada Yellowhead Highway and is home to the University of Saskatchewan. “We lived close to the University,” she shared. “My...

prostate cancer

Prostate Cancer Foundation and Movember Foundation Announce 2018 Winners of Challenge Awards

The Prostate Cancer Foundation (PCF) and the Movember Foundation recently announced four new Movember Foundation–PCF Challenge Award teams at some of the world’s leading academic research institutions will receive a total of $3.5 million to support cross-disciplinary pioneering research toward the...

hematologic malignancies
immunotherapy

Logistics of CAR T-Cell Therapy in Real-World Practice

With the U.S. Food and Drug Administration (FDA) approvals of tisagenlecleucel (Kymriah)1 and axicabtagene ciloleucel (Yescarta),2 chimeric antigen receptor (CAR) T-cell therapy has moved into real-world practice, offering new potentially curative options for incurable hematologic malignancies. Its ...

global cancer care

CONCORD-3: Global Surveillance of Cancer Survival Trends, 2000–2014

In an article in The Lancet, Allemani et al reported findings from the CONCORD program for global surveillance of cancer survival trends updated through 2014 (CONCORD-3).   Study Details CONCORD-3 includes data on 37.5 million patients diagnosed with cancer between 2000 and 2014 from...

breast cancer

Renowned Breast Cancer Researcher, Angela Hartley Brodie, PhD, Dies at 82

Angela Hartley Brodie, PhD, Professor Emeritus in the Department of Pharmacology at the University of Maryland School of Medicine, and an internationally recognized scientist whose groundbreaking cancer research is considered among the greatest advances in treating breast cancer, passed away on...

leukemia

Venetoclax Achieves Durable and Deep Remissions in CLL

Preliminary study results suggest that venetoclax (Venclexta) plus rituximab (Rituxan) is a highly active combination in relapsed/refractory chronic lymphocytic leukemia (CLL), achieving durable responses and minimal residual disease negativity in previously treated patients. “The results of our...

pancreatic cancer

Hydroxychloroquine Boosts Antitumor Activity of Neoadjuvant Chemotherapy for Pancreatic Cancer

Adding hydroxychloroquine, an inhibitor of autophagy, to neoadjuvant chemotherapy for pancreatic cancer increases its efficacy and alters the tumor’s molecular profile in a way that may render the tumor more susceptible to immune checkpoint inhibitors, according to interim data from a phase II...

survivorship
colorectal cancer

Expert Point of View: Patrick S. Sullivan, MD

”This was a great study and novel, asking what longer-term survivors with colon cancer are dying from—the toxicity of our treatment or population-risk illnesses?” commented session co-moderator, Patrick S. Sullivan, MD, Assistant Professor of Surgery and Chief Quality Officer, Division of Surgical ...

survivorship
colorectal cancer

Common Causes of Death Predominate Among Long-Term Colorectal Cancer Survivors

Patients with colorectal cancer who survive at least 5 years are increasingly likely to die from causes that are common in the general population, highlighting the importance of screening and lifestyle modification, suggested a large cohort study conducted in California.1 The analysis of more than...

multiple myeloma

Expanding Role Seen for Minimal Residual Disease in Managing Multiple Myeloma

Minimal residual disease is a promising biomarker for guiding the management of multiple myeloma that is becoming increasingly important with the advent of more efficacious therapies, according to emerging data and expert opinion. “The story of minimal residual disease in multiple myeloma is like...

breast cancer

Expert Point of View: Kelly M. McMasters, MD, PhD

“More and more, we are finding that traditional anatomic TNM staging has significant limitations in predicting prognosis, especially in such cases where response to therapy is an important consideration,” commented session moderator Kelly M. McMasters, MD, PhD, a surgical oncologist at the...

breast cancer

Neo-Bioscore Improves Staging of Breast Cancer Treated With Neoadjuvant Chemotherapy

A new score that incorporates tumor biology and response outperforms conventional histopathologic criteria for the staging of breast cancer treated with neoadjuvant chemotherapy, finds a retrospective validation cohort study.1 Investigators led by John R. Bergquist, MD, MS, MA, a general surgery...

gastrointestinal cancer

Expert Point of View: Daniel G. Coit, MD

“While these results are clearly superior to historical controls, the study prompts a number of questions,” session moderator, ­Daniel G. Coit, MD, a surgical oncologist at Memorial Sloan Kettering Cancer Center in New York, commented in an interview. “Nearly half of the patients received systemic ...

gastrointestinal cancer

Hyperthermic Intraperitoneal Chemoperfusion May Be Efficacious for Peritoneal Metastases

Hyperthermic intraperitoneal chemoperfusion is efficacious when used as part of multimodality therapy for low-volume peritoneal metastases of gastric cancer, suggests a prospective single-arm phase II trial.1 Among the 19 patients enrolled, all of whom had stage IV disease with ­either...

breast cancer

Expert Point of View: Steven L. Chen, MD

“Dr. Neuman and colleagues point out that patients often will seek out information on their diagnosis preconsultation,” commented session co-moderator Steven L. Chen, MD, a surgical oncologist with OasisMD in San Diego. “Their study demonstrates that the provision of high-quality information can...

breast cancer

Decision Aid Improves Breast Cancer Patients’ Knowledge of Surgical Options

A Web-based decision aid that allows women with early breast cancer to easily compare surgical treatment options helps them make more informed decisions, suggests a randomized trial reported at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 “Having knowledge of surgical...

colorectal cancer

Expert Point of View: Kelly M. McMasters, MD, PhD

“Several gene-expression profiles have been evaluated to predict prognosis in colorectal cancer, but none have become widely accepted or U.S. Food and Drug Administration–approved. This has important implications for deciding which patients may benefit from adjuvant chemotherapy,” commented...

colorectal cancer

Machine Learning Model Predicts Colorectal Cancer Recurrence

A machine learning model that uses a set or ensemble of algorithms has good accuracy for predicting colorectal cancer recurrence, investigators reported during a plenary session at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 Persistent key questions in managing early...

lung cancer

Immunotherapy Challenges in Lung Cancer: From Patient Selection to Clinical and Financial Toxicity

Immunotherapy has been a major advance in lung cancer, but it is not without its challenges, according to Sanjay Popat, PhD, FRCP, a consultant medical oncologist and reader in cancer medicine at the Royal Marsden Hospital, London, UK. He reviewed some of the challenges pertaining to the use of...

lung cancer

Expert Point of View: David Planchard, MD, PhD, Luboš Petruželka, MD, PhD, and Clarissa ­Baldotto, MD, MSc

Three invited discussants explored the results of these recent immunotherapy studies in lung cancer as well as their potential clinical implications at the International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer. KEYNOTE-021 trial “Pembrolizumab (Keytruda) is...

lung cancer

Immunotherapy Combinations Gain Traction in Lung Cancer

Combining immunotherapies with each other or with other agents such as chemotherapy and growth factor inhibitors holds promise for better tapping their benefit in patients with lung cancer, data from several studies suggest. Results show that strategic combinations can achieve higher response...

lung cancer

Expert Point of View: Paul Mitchell, MD

“This is a very important systematic review,” commented invited discussant, Paul Mitchell, MD, Associate Professor at the Olivia Newton-John Cancer and Wellness Centre in Melbourne, Australia. “There are theoretical reasons why programmed cell death ligand 1 (PD-L1) inhibitors might cause less...

lung cancer

Efficacy, Toxicity on a Par for Different Classes of Immune Checkpoint Inhibitors

The two main classes of immune checkpoint inhibitors used to treat non–small cell lung cancer (NSCLC) have essentially the same efficacy and toxicity profiles, according to a systematic review and meta-analysis of 23 trials with a total of 5,899 patients.1 Results showed that about one-fifth of...

lung cancer

Expert Point of View: Leora Horn, MD, MSc

The KEYNOTE-028 results confirm that pembrolizumab ­(Keytruda) is active in extensive-stage small cell lung cancer (SCLC) and lay to rest safety concerns stemming from the higher risk of paraneoplastic syndromes in this disease, according to invited discussant, Leora Horn, MD, MSc, Clinical...

lung cancer

Durable Responses Reported With Pembrolizumab in Heavily Pretreated Extensive-Stage Small Cell Lung Cancer

The programmed cell death protein 1 (PD-1) inhibitor pembrolizumab (Keytruda) has shown durable antitumor activity in patients with extensive-stage small cell lung cancer (SCLC) that expresses programmed cell death ligand 1 (PD-L1), according to an update of the KEYNOTE-028 trial.1 “Median overall ...

lung cancer

Combination Immunotherapy for Lung Cancer: The Wave of the Future

Increasing experience with immunotherapy for lung cancer in both the lab and the clinic is helping to refine treatment approaches and point the way forward, according to Naiyer Rizvi, MD, Director of both Thoracic Oncology and Immunotherapeutics at Columbia University Medical Center in New York....

Expert Point of View: Allen Cheng, MD, DDS; Susan D. ­McCammon, MD

The study findings by Dr. ­Buchakjian and colleagues suggest it may be time to revisit the significance of frozen margin status, according to one of the session co-moderators, Allen Cheng, MD, DDS, of the Providence Cancer Center and Head & Neck Surgical Associates, both in Portland, Oregon....

head and neck cancer

Specimen Margin Tops Frozen Margin as Prognostic Marker in Oral Cancer Surgery

Intraoperative frozen margins from the tumor bed help to assess the prognosis of oral cancer, but the permanent specimen margin remains king, according to a retrospective cohort study reported at the 9th International Conference on Head and Neck Cancer.1 Results indicated that the rate of local...

Expert Point of View: Benjamin L. ­Judson, MD

“This (adverse cardiac effects of chemotherapy) is a difficult problem to address because the side effects of chemotherapy in terms of its impact on the heart show up many years, sometimes decades, later. So that makes it harder to study and treat. It’s a real problem,” commented session...

head and neck cancer

Testosterone Therapy May Be Cardioprotective in Patients Undergoing Chemotherapy

The anabolic hormone testosterone may lessen the early adverse cardiovascular effects of chemotherapy and chemoradiation for advanced or recurrent cancer, according to a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1 Among the patients studied,...

Expert Point of View: Brian Burkey, MD, MEd

“This study pointed out what most head and neck/reconstructive surgeons know: Complex free flap reconstructions are associated with a relatively high readmission rate,” commented session co-moderator Brian Burkey, MD, MEd, Vice Chairman and Section Head of Head & Neck Surgery and Oncology, Head ...

head and neck cancer

Predictors of Readmission in Patients Requiring Free Tissue Reconstruction for Head and Neck Cancer

Certain factors increase the risk of unplanned readmission in the month after head and neck cancer resection requiring free tissue reconstruction, finds an analysis of data from the National Surgical Quality Improvement Program (NSQIP) of the American College of Surgeons.1 Nearly 1 in 10 patients...

Expert Point of View: M. Boyd Gillespie, MD, MSCR

“This study is actually surprising to me, because earlier studies of that particular antibody as a single therapy for this disease, salivary duct carcinoma, showed it was not very effective, with only 10% to 15% response rates,” session co-moderator, M. Boyd Gillespie, MD, MSCR, Professor and Vice ...

head and neck cancer

Good Showing for Trastuzumab/Docetaxel Combination Against Salivary Gland Carcinoma

The combination of trastuzumab (Herceptin) and docetaxel seems to be highly active in patients with unresectable advanced HER2-positive salivary gland carcinoma of the ductal subtype, according to interim data from an open-label, single-arm phase II trial.1 More than two-thirds of patients had a...

Expert Point of View: Michael L. Hinni, MD

“Endoscopic transoral surgeons have used corticosteroids for years before, during, and after transoral operations to prevent presumptive airway edema and to reduce the risks of tracheostomy,” commented one of the session co-moderators, Michael L. Hinni, MD, Chair of the Department of...

head and neck cancer

Benefits Seen From Extending Steroids After Transoral Robotic Surgery for Head and Neck Cancer

Patients undergoing transoral robotic surgery for head and neck cancer may experience improvements in some outcomes when given an extended course of corticosteroids, finds a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1 Relative to peers given...

Expert Point of View: William B. Armstrong, MD

“This work is intriguing and may have clinical potential,” commented session co-moderator William B. Armstrong, MD, Professor of Clinical Otolaryngology–Head and Neck Surgery and Chair, Department of Otolaryngology–Head and Neck Surgery, at the University of California, Irvine, Orange, ...

head and neck cancer

Nerve Stimulation During Oncologic Neck Dissection May Help to Preserve Shoulder Function

Electrical stimulation of the spinal accessory nerve during neck dissection for head and neck cancer may reduce the development of shoulder dysfunction, according to a double-blind randomized controlled trial.1 A year after surgery, patients given intraoperative electrical stimulation had...

head and neck cancer

Use of Lugol’s Iodine Stain May Reduce the Need for Repeat Resection of Oral and Oropharyngeal Cancers

By identifying residual dysplasia in the tumor bed, Lugol’s iodine staining may improve pathologic outcomes with resection of oral and oropharyngeal cancers, according to interim findings of a UK randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1...

2016 ASCO Annual Meeting Planning Committees

The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with nearly 30,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees and thank them for their time and...

SIDEBAR: Novel Agents Are Still Needed to Address Cytopenias in Myelofibrosis

Despite improving splenomegaly and symptoms in patients with myelofibrosis, ruxolitinib has not been helpful for managing cytopenias in this population, according to Wendy Stock, MD, of the University of Chicago. “Additional trials are underway with novel [JAK] inhibitors, with some hints about...

leukemia

Improvements Highlighted in Treatment of Leukemias and Preleukemias

Certain preleukemic conditions and leukemia in high-risk patients have remained challenging to treat despite advances in hematology, according to Wendy Stock, MD, of the University of Chicago. But studies reported at the Best of ASCO® Annual Meeting ‘11 in Seattle show progress even in these ...

SIDEBAR: Questions and Answers about Adjuvant Imatinib in GIST

"As clinicians, we really need to ask who should receive adjuvant [imatinib], and we have several ways to risk-stratify patients, including tumor characteristics (size, location, mitotic index), mutational analyses, and a recently published nomogram for patient-specific survival,” said William D....

sarcoma

Novel Approaches and Agents Making Headway against Sarcoma

Novel approaches and agents reported at the ASCO 2011 Annual Meeting are improving outcomes in sarcoma, a heterogeneous disease with historically poor outcomes, according to William D. Tap, MD, Section Chief of Sarcoma Oncology at Memorial Sloan-Kettering Cancer Center in New York. Dr. Tap...

SIDEBAR: A Cautious Approach to Maintenance Therapy

Hematologists should weigh the risks and benefits carefully when considering lenalidomide (Revlimid) or other maintenance therapy for their patients with myeloma, according to William I. Bensinger, MD, of the Fred Hutchinson Cancer Research Center, Seattle. Lenalidomide is associated with...

multiple myeloma

Multiple Myeloma Research Spotlights Treatment Concerns and Advances

Myeloma data reported at this year’s ASCO meeting raise concern about the safety of a mainstay class of drugs in this disease, while also hinting at good efficacy of some novel drugs and approaches, according to William I. Bensinger, MD, of the Fred Hutchinson Cancer Research Center, Seattle....

SIDEBAR: Research Is Taking the Guesswork Out of Lymphoma Management

The selected studies answer some critical questions in lymphoma that hematologists face daily and that have been the source of intense debate in the field, according to Oliver Press, MD, PhD, of the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle. “I think the...

lymphoma

Similar Outcomes Confirmed in Variety of Lymphoma Treatment Comparisons

Three abstracts reported at the Best of ASCO® meeting in Seattle provide guidance to hematologists when it comes to long-standing gray areas in lymphoma management, according to Oliver Press, MD, PhD, of the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle....

SIDEBAR: Will East-West Differences Limit Transferability of Clinical Trial Results?

Differences in patients’ tumor characteristics and in surgical practices between eastern and western countries may limit the transferability of clinical trial results in early gastric cancer, according to Dr. Lockhart. One major difference is tumor location. For example, in the Asian CLASSIC...

Advertisement

Advertisement



Advertisement